5.12
間接作用性コリン作動薬は、アセチルコリンエステラーゼ酵素と相互作用し、アセチルコリンをコリンとアセテートに分解するのを防ぐため、シナプス間隙でのアセチルコリンの濃度が増加します。これらの作動薬は、作用時間に基づいて可逆的なものと不可逆的なものに分類できます。
可逆的な阻害剤は、短~中程度の作用時間を…
間接作用型コリン作動性アゴニストは、シナプス間隙でAChE酵素に結合し、ACh加水分解を阻害します。これにより、シナプスでのAChの濃度が増加し、間接的にコリン作動性作用が増強されます。
一般に、それらは作用持続時間に基づいて可逆的または不可逆的な阻害剤のいずれかに分類されます。
可逆的阻害剤は、短時間作用型および中間作用型薬剤です。
短時間作用型薬剤は、エドロフォニウムなどの第四級アンモニウム基を持つ単純なアルコールです。
中間作用型薬剤には、ネオスチグミンやフィゾスチグミンなどのカルバミン酸エステルが含まれます。
ネオスチグミンは第四級アンモニウム基を持つカルバメートであり、フィゾスチグミンは第三級アミン基を持つ天然に存在するカルバメートです。
不可逆的な阻害剤には、有機リン酸塩が含まれます。リン酸誘導体は複数の置換基を持つもので、置換基の1つが不安定な基として機能します。
例えば、エコーチオファイトは2つのアルコキシ基と1つのチオコリン基から構成されています。神経ガスであるサリンには、アルコキシ基が1基、アルキル基が1基、ハロゲン基が1基ずつあります。ここで、チオコリンとハロゲンは不安定な基です。
View the full transcript and gain access to JoVE Core videos
Q1: How do indirect-acting cholinergic agonists increase acetylcholine levels at the synapse?
Indirect-acting cholinergic agonists bind to acetylcholinesterase (AChE) enzymes at the synaptic cleft and inhibit the breakdown of acetylcholine into choline and acetate. By preventing ACh hydrolysis, these agents allow acetylcholine to accumulate in the synapse, indirectly enhancing cholinergic neurotransmission without directly activating cholinergic receptors.
Q2: What is the difference between reversible and irreversible cholinesterase inhibitors?
Reversible inhibitors are short- and intermediate-acting agents that temporarily bind to acetylcholinesterase, allowing enzyme recovery. Irreversible inhibitors, such as organophosphates, permanently inactivate the enzyme through covalent bonding. Reversible agents like neostigmine and physostigmine have predictable durations of action, while irreversible inhibitors produce prolonged effects.
Q3: What structural features distinguish short-acting reversible cholinesterase inhibitors?
Short-acting reversible inhibitors are simple alcohols bearing quaternary ammonium groups, exemplified by edrophonium. The quaternary ammonium moiety provides positive charge, enhancing binding to the negatively charged active site of acetylcholinesterase. This structural feature enables rapid, reversible enzyme inhibition with brief duration of action.
Q4: How do intermediate-acting agents like neostigmine and physostigmine differ structurally?
Both neostigmine and physostigmine are carbamic esters, but they differ in amine groups and origin. Neostigmine is a synthetic carbamate with a quaternary ammonium group, while physostigmine is a naturally occurring carbamate containing a tertiary amine group. These structural differences affect their pharmacokinetic properties and tissue penetration.
Q5: What makes organophosphates irreversible cholinesterase inhibitors?
Organophosphates are phosphoric acid derivatives containing multiple substituents, including a labile group that forms a covalent bond with acetylcholinesterase. Echothiophate contains two alkoxy groups and a thiocholine labile group, while sarin contains an alkoxy group, alkyl group, and halogen labile group. This covalent modification permanently inactivates the enzyme.
Q6: Why are quaternary ammonium groups important in cholinesterase inhibitor design?
Quaternary ammonium groups provide permanent positive charge, enabling strong electrostatic interactions with the negatively charged active site of acetylcholinesterase. This structural feature enhances binding affinity and specificity for the enzyme. Agents like edrophonium and neostigmine utilize quaternary ammonium moieties to achieve potent cholinesterase inhibition.
Q7: How do the labile groups in organophosphates contribute to their irreversible action?
Labile groups in organophosphates, such as the thiocholine in echothiophate or the halogen in sarin, are readily displaced during enzyme binding. This displacement allows the phosphorus atom to form a stable covalent bond with a serine residue in the acetylcholinesterase active site. The resulting phosphorylated enzyme cannot hydrolyze acetylcholine, producing irreversible inhibition.